HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update. Business and Clinical Program Updates: TTI-109 – Ulcerative Colitis (UC) Advan

Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program The Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containment Lucid Capital Market

- Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per share TARPON SPRINGS, Fla., November 13, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today reported financial results for the third quarter ended September 30, 2026, and prov

The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on data from the Phase 3 HIBISCUS trial showing efficacy and safety results in adolescents and adults living with sickle cell disease 1 Sickle cell disease is a progressive, life-threatening, debilitating blood disease with limited disease-modifying therapeutic options that affects an estimated 100,000 Americans, 110,000 Europeans – and around 8 million people worldwide 2-4 E

SAN DIEGO , Nov. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal second quarter ended September 30, 2026, and provided a corporate update. Corporate Updates Merger On September 17, 2026, we entered into a Plan of Merger and Reorganization (the "Merger Agreement") with North Immunology, Inc. ("North Immunology") and two wholly owned subsidiaries of the Company,

ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect preliminary ERAS-4001 data in H2 2026 and ERAS-0015 data in H1 2027 Cash, cash equivalents, and marketable securities of $948 million as of September 30, 2026 SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -

Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients The BB-301 pivotal trial remains on track to begin in mid-2027 Well-capitalized with cash, as of September 30, 2026, of approximately $176 million Ben

SAN FRANCISCO , Nov. 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025. "This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development," said Howard Robin, President and Chief Executive Offic

JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027 JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027 JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027 Cash, cas

FDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001 TAIPEI, Taiwan, Nov. 12, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted its request for an INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs)